Humacyte Receives Nasdaq Notice for Failing $1 Bid-Price Rule

What Happened

• Humacyte, Inc. (HUMA) filed an 8-K on July 31, 2026, disclosing that Nasdaq notified the company its common stock’s closing bid price was below the $1.00 minimum for 30 consecutive business days (period ended July 30, 2026).
• Under Nasdaq Listing Rule 5450(a)(1) and rule 5810(c)(3)(A), the company has been given an initial 180-calendar-day compliance period, until January 27, 2027, to regain compliance by achieving a closing bid price of at least $1.00 per share for 10 consecutive business days. The notice does not have any immediate effect on the listing; HUMA continues to trade on The Nasdaq Global Select Market under the ticker “HUMA.”

Key Details

• 30 consecutive business days below $1.00: period ended July 30, 2026.
• Compliance deadline: January 27, 2027 (180 calendar days from notice).
• Regain requirement: closing bid ≥ $1.00 for at least 10 consecutive business days.
• Company will monitor the stock price and consider options to achieve compliance; it also included standard forward-looking statements and risk-factor references to its 2025 Form 10-K and 2026 Form 10-Q.

Why It Matters

• If Humacyte does not meet the $1.00 bid-price requirement by the deadline, Nasdaq could begin delisting proceedings, which may reduce liquidity and make trading or accessing capital more difficult.
• There is no immediate change to trading or reporting, but investors should watch the stock’s daily close and company updates for progress or any corporate actions the company may take to regain compliance.